Ronna Hauser breaks down findings showing that delayed manufacturer refunds under the Medicare Drug Price Negotiation Program are forcing retail pharmacies to minimize high-dollar drug inventory and dip into savings to stay afloat.
Ronna Hauser, PharmD
Advertisement
Articles by Ronna Hauser, PharmD
TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.
Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan.
Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discusses concerns about the implementation of the MDPNP.
A recent analysis from NCPA showed potential weekly cash flow shortfalls for pharmacies and annual revenue losses.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5